{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.9","upperLimit":"16.0","value":"8.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Time to Response was defined as the time from the first dose of study treatment to the initial documented response (CR or CRu, or PR)","dispersionType":"Full Range","groups":[{"description":"Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity","id":"OG000","title":"Lenalidomide"}],"paramType":"MEDIAN","populationDescription":"Participants with a response of PR or better.","reportingStatus":"POSTED","timeFrame":"From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks","title":"Time to Response","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"weeks"}